Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

Table 1 Virological and immunological characterization of the patients

Patient	Sampling year	Age (Years)	Viral load (RNA copies/ml plasma)	Viral tropism^a	Number of CD4⁺T cells/μl (%)	Drug regimen	Disease stage^b
Child 1	1998	0.11^c	<200	R5	5342 (47)	-	N
	1999	1	<200	nd	2992 (50)	-	N
	2000	2	1355	R5	2919 (43)	-	A1
	2001	3	nd	nd	3253 (51)	-	A1
	2003	5	20968	X4	595 (27)	d4T + 3TC + LPV/RTV	B2
	2006	8	<200	nd	1895 (55)	d4T + 3TC + LPV/RTV	A1
	2010	12	<40	nd	1878 (54)	3TC + ABC + LPV/RTV	A1
Child 2	1992	0.07^d	<200	R5^e	1670 (52)	AZT	C1
	1997	5	<200	X4	1050 (25)	AZT	C1
	1999	7	13883	nd	127 (15)	AZT	C1
	2001	9	1250	X4	44 (5)	AZT + 3TC	C3 (death)

^aAs determined phenotypically in TZMbl cells [22] or genotypically based on V3 loop sequence patterns [36]; ^bAccording to the CDC revised classification system for HIV infection in children; ^cFirst blood collection was at day 39 after birth; ^dFirst blood collection was at day 27 after birth; ^eIsolate obtained at birth was syncytium inducing as determined in PBMCs and several cell lines [32]; d4T–stavudine, 3TC–lamivudine, LPV–lopinavir, RTV–ritonavir, ABC–abacavir, AZT–zidovudine; nd–not determined.

ISSN: 1742-4690